As shown in Figures 1d and e, 16-h treatment with erlotinib induced a marked increase of E-cadherin and a substantial decrease of fibronectin expression resulting in a marked increase in E-cadherin/fibronectin (E/F) ratio, indicating that short-term blockade of EGFR signaling could be effective at reducing mesenchymal NSCLC traits. Here, EGFR is linked to non-small cell lung carcinoma.